Trials / Unknown
UnknownNCT00176020
Nicotinic Acid - Pharmacokinetics, Pharmacodynamics, Receptor Expression
Double-Blind, Randomized, Placebo-Controlled, Single-Center, 2 Treatment, 3-Way Crossover Study to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of a Single Oral Repeated Dose of 500 Mg Nicotinic Acid as Tablets in Healthy Subjects
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (planned)
- Sponsor
- Heidelberg University · Academic / Other
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The study will be a double-blind, randomized, placebo-controlled, single-center, 2 treatment, 3--way crossover. Subjects will be randomly allocated to a treatment sequence - AAB, ABA or BAA. The two treatments will be: * Treatment A: 500 mg nicotinic acid (Niacor(R)) * Treatment B: Niacor(R) Placebo Each trial period will last one day, there will be a wash-out period of at least 2 days between each trial period. Five to seven days after study day 1 of trial period 3 there will be a final safety examination.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | nicotinic acid |
Timeline
- First posted
- 2005-09-15
- Last updated
- 2006-03-15
Source: ClinicalTrials.gov record NCT00176020. Inclusion in this directory is not an endorsement.